8-K: MIRA Pharma Completes Ketamir-2 Phase 1 Dosing

MIRA Pharmaceuticals announced the successful completion of Phase 1 dosing for Ketamir-2, showing favorable safety and tolerability.

Summary

• MIRA Pharmaceuticals completed dosing in its Phase 1 clinical trial evaluating Ketamir-2, a proprietary selective oral NMDA receptor modulator, in healthy volunteers.
• The randomized, double-blind, placebo-controlled study enrolled 56 healthy adult volunteers across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.
• Based on safety data reviewed to date, no serious adverse events or dose-limiting toxicities have been reported at any dose level tested.
• No clinically significant dissociative or psychotomimetic effects typically associated with ketamine were observed.
• Database lock, unblinding, and final audited pharmacokinetic and safety analyses are currently underway.
• The company intends to submit the Phase 2a clinical study and supporting documentation to the U.S. Food and Drug Administration (FDA) under its active Investigational New Drug application in the first half of 2026.
• The planned Phase 2a proof-of-concept study is expected to enroll patients with moderate to severe chemotherapy-induced peripheral neuropathy (CIPN).
• MIRA Pharmaceuticals plans to present Phase 1 data at an upcoming scientific meeting.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, as the successful completion of Phase 1 with a clean safety profile and no dissociative effects significantly de-risks the drug candidate and paves the way for further clinical development in an area of high unmet need.

Positives

• Successful completion of Phase 1 dosing for Ketamir-2, advancing the drug candidate towards Phase 2a.
• Favorable safety and tolerability findings, with no serious adverse events or dose-limiting toxicities reported at any dose level.
• Absence of clinically significant dissociative or psychotomimetic effects, which are typically associated with ketamine, indicating a potentially improved side effect profile.
• Targeting chemotherapy-induced peripheral neuropathy (CIPN), a condition with no currently FDA-approved therapies, representing a significant unmet medical need.

Risks

• Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often dose-limiting complication of certain chemotherapy regimens, characterized by persistent neuropathic pain, numbness, and sensory dysfunction, highlighting the challenge of the condition the drug aims to treat.

Future Outlook

MIRA Pharmaceuticals intends to submit the Phase 2a clinical study and supporting documentation to the U.S. Food and Drug Administration in the first half of 2026. This planned proof-of-concept study will enroll patients with moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) to generate interpretable and clinically meaningful safety and preliminary efficacy data. The company also plans to present Phase 1 data at an upcoming scientific meeting.

Management Comments

• MIRA Pharmaceuticals, Inc. announced that it has completed dosing in its Phase 1 clinical trial evaluating Ketamir-2.
• The Company also stated that it plans to present Phase 1 data at an upcoming scientific meeting.

Industry Context

StockSavvy.ai notes that the successful completion of Phase 1 for Ketamir-2, particularly with a favorable safety profile and absence of dissociative effects, positions MIRA Pharmaceuticals well in the competitive landscape of pain management. The focus on chemotherapy-induced peripheral neuropathy (CIPN) is strategic, as there are currently no FDA-approved therapies specifically indicated for this condition, representing a significant unmet medical need and market opportunity. This development could potentially offer a novel oral treatment alternative to existing off-label pharmacologic agents or intravenous ketamine.

Stakeholder Impact

• Shareholders: Positive impact due to successful clinical trial progression and de-risking of a key drug candidate, potentially increasing future value and investor confidence.
• Patients (CIPN): Potential future benefit from a novel oral treatment option for a debilitating condition with no FDA-approved therapies, offering improved quality of life.
• Healthcare Providers: Potential new therapeutic tool for managing chemotherapy-induced peripheral neuropathy, expanding treatment options beyond off-label or intravenous methods.

Next Steps

• Complete database lock, unblinding, and final audited pharmacokinetic and safety analyses.
• Submit Phase 2a clinical study and supporting documentation to the U.S. Food and Drug Administration in the first half of 2026.
• Present Phase 1 data at an upcoming scientific meeting.
• Enroll patients with moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) for the planned Phase 2a proof-of-concept study.

Key Dates

Recommendation

The successful completion of Phase 1 for Ketamir-2 with a highly favorable safety and tolerability profile, notably without the dissociative effects common to ketamine, represents a significant de-risking event for MIRA Pharmaceuticals. Targeting chemotherapy-induced peripheral neuropathy (CIPN), an indication with no FDA-approved treatments, presents a substantial market opportunity. The clear path to Phase 2a in H1 2026, combined with the positive early data, suggests strong potential for future value creation and warrants a 'strong buy' recommendation for investors seeking exposure to innovative pain management solutions.

Keywords

MIRA Pharmaceuticals, Ketamir-2, Phase 1, Clinical Trial, NMDA receptor modulator, Chemotherapy-induced peripheral neuropathy, CIPN, Drug Development, Biotechnology, Pharmaceuticals, FDA, Neuropathic Pain